Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Study to Investigate the Effect of Changes in Dentinal Hypersensitivity on Oral Health Parameters

12 de agosto de 2026 atualizado por: HALEON
This exploratory study will investigate the effect of long-term management of Dentine Hypersensitivity (DH) by use of a sensitivity toothpaste on selected oral health parameters, such as changes in oral hygiene (as measured by supra-gingival plaque accumulation), with associated changes in gingival health.

Visão geral do estudo

Status

Concluído

Intervenção / Tratamento

Descrição detalhada

This is a single center, non-comparative design study to investigate the effect of long-term management of DH by use of a sensitivity toothpaste on selected oral health parameters, such as changes in oral hygiene, with associated changes in gingival health. Sufficient participants will be screened to ensure approximately 70 eligible participants get allocated the study toothpaste in order to ensure that approximately 60 participants complete the study.

Tipo de estudo

Intervencional

Inscrição (Real)

75

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • Cheshire
      • Ellesmere Port, Cheshire, Reino Unido, CH65 4BW
        • Intertek CRS Ltd

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

  • Adulto
  • Adulto mais velho

Aceita Voluntários Saudáveis

Sim

Descrição

Inclusion Criteria:

  • Demonstrates understanding of the study and willingness to participate as evidenced by voluntary written informed consent and has received a signed and dated copy of the informed consent form.
  • Understands and is willing, able and likely to comply with all study procedures and restrictions.
  • Good general and mental health with, in the opinion of the investigator,

    1. No clinically significant or relevant abnormalities of medical history or oral examination which could impact study outcomes.
    2. The absence of any condition that would impact on the participant's safety or wellbeing or affect the individual's ability to understand and follow study procedures and requirements.
  • At screening, self-reported history of DH lasting more than 6 months but not more than 10 years.
  • At screening, minimum of two accessible teeth (incisors, canines or pre-molars) that meet all of the following criteria:

    1. Tooth with signs of erosion, abrasion and/or facial/cervical gingival recession (EAR).
    2. Tooth with signs of sensitivity measured by qualifying evaporative (air) assessment.
  • At Baseline, minimum of two accessible teeth (incisors, canines or pre-molars), that meet the following criteria:

    1. Tooth with signs of sensitivity, measured by qualifying tactile stimulus (Yeaple less than or equal to [<=] 20 gram) and evaporative (air) assessment (Schiff Sensitivity Score greater than or equal to [>=] 2)

Exclusion Criteria:

  • Women who are known to be pregnant or who are intending to become pregnant over the duration of the study.
  • Women who are breast-feeding.
  • Known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients.
  • Clinical Study/Experimental Medication

    1. Participation in another clinical study or receipt of an investigational drug within 30 days prior to the screening visit.
    2. Participation in a tooth desensitizing treatment study within 8 weeks of the screening visit.
    3. Previous participation in this study.
  • Recent history (within the last year) of alcohol or other substance abuse.
  • An employee of the sponsor or the study site or members of their immediate family.
  • Disease

    1. Presence of chronic debilitating disease which, in the opinion of the investigator, could affect study outcomes.
    2. Any condition which, in the opinion of the investigator, is causing xerostomia.
  • General Dentition Exclusions

    1. Dental prophylaxis within 4 weeks of screening.
    2. Tongue or lip piercing
    3. Desensitizing treatment within 8 weeks of screening (professional sensitivity treatments and non-dentifrice sensitivity treatments).
    4. Treatment of periodontal disease (including surgery) within 12 months of screening, scaling or root planing within 3 months of screening.
    5. Teeth bleaching within 8 weeks of screening.
    6. Current active caries or periodontitis which, in the opinion of the investigator, could affect study outcomes, or the health of the subject if they participate in the study.
    7. Partial dentures, orthodontic appliances or dental implants which, in the opinion of the investigator, could affect study outcomes.
    8. Restorations in a poor state of repair which, in the opinion of the investigator, could affect study outcomes.
  • Specific Dentition Exclusions for Teeth Selected for Sensitivity Assessments

    1. Tooth with evidence of current or recent caries or reported treatment of decay in 12 months of screening.
    2. Tooth with exposed dentine but with deep, defective or facial restorations, teeth used as abutments for fixed or removable partial dentures, teeth with full crowns or veneers, orthodontic bands or cracked enamel. Sensitive teeth with contributing aetiologies other than erosion, abrasion or recession of exposed dentine.
    3. Sensitive tooth not expected, in the opinion of the investigator, to respond to treatment with an over-the-counter toothpaste.
  • Use of a sensitivity oral care product within 8 weeks of screening.
  • Any participants who, in the opinion of the investigator, should not participate in the study, use of medication which could interfere in the outcome of the study or require antibiotic prophylaxis for dental procedures.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: N / D
  • Modelo Intervencional: Atribuição de grupo único
  • Mascaramento: Solteiro

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Test Toothpaste
Participants will brush with the test toothpaste using a manual toothbrush for 1 timed minute twice daily (morning and evening) for 24 weeks.
Marketed toothpaste containing 5 percent (%) weight by weight (w/w) NovaMin / 1426 parts per million (ppm) fluoride as sodium monofluorophosphate (SMFP)

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Change From Baseline in Schiff Sensitivity Score
Prazo: Baseline and up to Week 24
Evaporative (air) sensitivity will be assessed by the participant's response to an evaporative (air) stimulus administered by the clinical examiner. Participant response will be evaluated immediately following application of the stimulus using the Schiff sensitivity scale (0= Participant does not respond to air stimulation, 1= Participant responds to air stimulus but does not request discontinuation of stimulus, 2= Participant responds to air stimulus and requests discontinuation or moves from stimulus, 3= Participant responds to stimulus, considers stimulus to be painful, and requests discontinuation of stimulus). A decrease in Schiff sensitivity score indicates improvement. Change from Baseline will be calculated by subtracting Baseline score from the score at the indicated timepoints.
Baseline and up to Week 24
Change From Baseline in Tactile Threshold
Prazo: Baseline and up to Week 24
Tactile sensitivity will be assessed by the participant's response to a tactile stimulus administered by the clinical examiner using a constant pressure probe (Yeaple probe). After each application of the stimulus, the participant will be asked to indicate whether they experienced any pain or discomfort (yes/no response). The pressure setting with two consecutive 'yes' responses will be recorded as the tactile threshold in gram. An increase in tactile threshold (gram) indicates improvement. Change from Baseline will be calculated by subtracting Baseline value from the value at the indicated timepoints.
Baseline and up to Week 24
Change From Baseline in Labelled Magnitude Scales (LMS) Score
Prazo: Baseline and up to Week 24
The tooth sensitivity questionnaire will be used to describe the overall tooth sensitivity experienced by the participant. Participants will indicate whether they have felt tooth sensitivity during the previous 24 hours. Participants who indicate they did feel tooth sensitivity will complete the remainder of the questionnaire and rate the intensity, duration, tolerability and descriptive quality of their tooth sensitivity using the four individual 100 millimeter (mm) LMS. Participants will mark each scale to indicate the best description of their sensitivity and the marked-off line segment will be measured in 'mm'. Lower scores indicate an improvement in sensitivity. Change from Baseline will be calculated by subtracting Baseline score from the score at the indicated timepoints.
Baseline and up to Week 24

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Change From Baseline in Turesky Plaque Index (TPI)
Prazo: Baseline and up to Week 24
TPI will be used to assess plaque on all gradable teeth. The plaque will first be disclosed using a plaque disclosing dye solution. The TPI will be assessed on the facial and lingual surfaces of each scorable tooth. Three scores will be recorded buccally/labially and three scores lingually/palatally. Disclosed plaque will be scored on a scale ranging from 0-6, where 0= No plaque, 1= Slight flecks of plaque at the cervical margin of the tooth, 2= Thin continuous band of plaque (up to 1 mm) at the cervical margin of the tooth, 3= Band of plaque wider than 1 mm but covering less than (<)1/3 of the area, 4= Plaque covering at least 1/3 but less than 2/3 of the area, 5= Plaque covering 2/3 or more of the crown of the tooth. Lower score indicates improvement in the symptoms. Change from Baseline will be calculated by subtracting the Baseline score from the score at the indicated timepoints.
Baseline and up to Week 24
Change From Baseline in Modified Gingival Index [MGI]
Prazo: Baseline and up to Week 24
The MGI assessment is a non-invasive evaluation which focuses on the visual symptoms of gingivitis. It will be assessed on the facial and lingual surfaces of each scorable tooth using a 5-point scale ranging from 0 to 4, where 0= absence of inflammation 1= mild inflammation; slight change in color, little change in color; little change in texture of any portion of the marginal or papillary gingival unit. 2= mild inflammation; criteria as above but involving the entire marginal or papillary gingival unit. 3= moderate inflammation; glazing, redness, oedema, and/or hypertrophy of the marginal or papillary gingival unit. 4= severe inflammation; marked redness, oedema and/or hypertrophy of the marginal or papillary gingival unit, spontaneous bleeding, congestion, or ulceration. Lower score indicates improvement in the symptoms. Change from Baseline will be calculated by subtracting the Baseline score from the score at the indicated timepoints.
Baseline and up to Week 24
Change From Baseline in Dentine Hypersensitivity Experience Questionnaire (DHEQ) Total Score
Prazo: Baseline and up to Week 24
The DHEQ is used to measure how DH affects participants quality of life. Section 2 has 34 questions in grouped into 5 domains (Restrictions, Adaptation, Social Impact, Emotional Impact, and Identity). Participants will score each question using a 7-point scale ranging from 1 to 7, where 1= strongly disagree, 2= disagree, 3= disagree a little, 4= neither agree nor disagree, 5= agree a little, 6= agree, and 7= strongly agree. The total score will be derived from the sum of scores across all domains and it ranges from 34 to 238. A lower score indicates a better quality of life regarding DH. Change from Baseline will be calculated by subtracting the Baseline score from the score at the indicated timepoints.
Baseline and up to Week 24

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

27 de agosto de 2013

Conclusão Primária (Real)

4 de março de 2014

Conclusão do estudo (Real)

4 de março de 2014

Datas de inscrição no estudo

Enviado pela primeira vez

12 de agosto de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

12 de agosto de 2026

Primeira postagem (Real)

17 de agosto de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

17 de agosto de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

12 de agosto de 2026

Última verificação

1 de agosto de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • RH01897

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

Anonymized individual participant data and study documents can be requested for further research from ww.clinical-trial-register@haleon.com

Prazo de Compartilhamento de IPD

IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.

Critérios de acesso de compartilhamento IPD

Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension can be granted, when justified, for up to another 12 months.

Tipo de informação de suporte de compartilhamento de IPD

  • PROTOCOLO DE ESTUDO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever